Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
HKG: 1177
Sino Biopharmaceutical’s KRAS Inhibitor Garsorasib Earns Breakthrough Designation in China
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has announced that its...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...
Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024
Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI)...
Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...
Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services
Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in...
Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...
Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...
Sino Biopharmaceutical Completes Enrollment for Phase III Trial of Anlotinib in Soft Tissue Sarcoma
Sino Biopharmaceutical Ltd (HKG: 1177), a China-based pharmaceutical giant, has announced the completion of patient...
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...
Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2%...
Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...